Abstract: Anemia is a condition in which red blood cells and/or hemoglobin (Hb) concentrations are decreased below the normal range, resulting in a lack of oxygen being transported to tissues and organs. Those afflicted with this condition may feel lethargic and weak, which reduces their quality of life. The condition may be manifested in inherited blood disorders, such as thalassemia and sickle cell disease, whereas acquired disorders include aplastic anemia, chronic disease, drug toxicity, pregnancy, and nutritional deficiency. The augmentation of fetal hemoglobin (HbF) results in the reduction in clinical symptoms in beta-hemoglobinopathies. Several transcription factors as well as medications such as hydroxyurea may help red blood cells produce more HbF. HbF expression increases with the downregulation of three main quantitative trait loci, namely, the XMN1-HBG2, HBS1L-MYB, and BCL11A genes. These genes contain single nucleotide polymorphisms (SNPs) that modulate the expression of HbF differently in various populations. Allele discrimination is important in SNP genotyping and is widely applied in many assays. In conclusion, the expression of HbF with a genetic modifier is crucial in determining the severity of anemic diseases, and genetic modification of HbF expression may offer clinical benefits in diagnosis and disease management.

Keywords: fetal hemoglobin; anemia; single nucleotide polymorphism; XMN1-HBG2; HBS1L-MYB; BCL11A

1. Introduction

Anemia is a common hematological condition in acquired and inherited disorders, with diverse pathophysiology, such as infections, iron deficiency, kidney disease, cancer, thalassemia, sickle cell disease (SCD), and hereditary persistence fetal hemoglobin (HPFH) [1–3]. Anemia is characterized by a decrease in normal hemoglobin concentration and, besides a reticulocyte count, is also classified according to mean corpuscular volume (MCV) due to altered red blood cell morphology that leads to microcytic, normocytic, and macrocytic anemias [1,4,5].

Increased HbF levels due to reactivation or overexpression of the HBG gene and subsequent production of γ-globin alleviate the severity of anemia, especially in hemoglobinopathies, such as SCD and thalassemia [6,7]. The risk of mortality and morbidity in those diseases are decreased in patients who have high levels of HbF [7]. High HbF levels can be due to the
effects of drugs, autoimmune disease, pregnancy, malignancy, diabetes, genetic modifiers, and other factors [8].

Genetic modifiers are known as single nucleotide polymorphisms (SNPs) [9–11]. SNPs are the most common type of human genetic variation, as shown in Figure 1. There are two types of SNPs: synonymous SNPs and nonsynonymous SNPs. Synonymous SNPs are known as silent SNPs due to unchanged amino acid, whereas nonsynonymous SNPs may produce disease by affecting amino acids [12]. Each SNP consists of a difference in a single DNA building block, called a nucleotide. For example, an SNP may replace the nucleotide alanine (A) with the nucleotide guanine (G) in a stretch of DNA. The polymorphism can occur by mutation, resulting in nucleotide changes, such as insertion, deletion, or rearrangement of a nucleotide. Therefore, SNPs are among the genetic polymorphisms that consist of a difference in DNA sequence among individuals, groups, or populations, with the production of altered proteins [13]. SNPs have advantages, which can provide genetic information such as ethnicity, physical traits, or phenotype and can be used as a genetic marker in the human genome for genetic mapping or studies of associations between polymorphism and disease or drug response [14–17]. The distribution of SNPs throughout genes has been an important biomarker in many applications, including quantitative trait loci mapping, pedigree analysis, and population genetics [18]. Moreover, the presence of SNPs may provide advantages in clinical diagnosis and disease management, such as for patients with blood disorders, who may be offered potential targeted therapies. However, SNPs also have limitations or disadvantages that affect the routine approach, such as the complement probabilities or discrimination power when more SNPs are present in assays. Yet, more loci and amplification products of SNPs will help make data clarification more strenuous and precise [16].

2. Fetal Hemoglobin

HbF is produced in a fetus at around six weeks of pregnancy and constitutes 98% of its total hemoglobin content until birth [19]. HbF consists of a heterogenous structure (2 α and 2 γ subunits), with two types of γ-globulin chains made of glycine and alanine. HbF has stronger oxygen binding than does adult hemoglobin (HbA), thus enabling the unborn child to draw oxygen from the mother’s blood. The switching from HbF to HbA occurs soon after birth. The HbF level declines to around five per cent of the total hemoglobin level in normal 6-month-old babies, and by the time they reach 2 years old, the level will have dropped to less than one per cent, where it remains throughout life.

HbA will become the main hemoglobin produced by the body, at 95% to 98% of the total Hb, followed by HbA2 (2.5% to 3.5%) [7]. The concentration of HbF is determined by
the production of the γ-globin chain, and the rise in HbF levels may ameliorate the severity of anemia in adults with blood disorders [20]. In adults, alterations in the HBB gene that produces the β-globin chain or point mutations upstream of the HBG gene (which produces the γ-globin chain) have been linked to unusually high γ-globin chain expression. The reactivation of HbF production may occur in certain acquired and inherited conditions. For example, alterations in the β-globin chain structure in SCD, β-thalassemia, δβ-thalassemia, and HPFH may lead to increased HbF production in red blood cells as the γ-globin chain is expressed as a compensatory mechanism [19,21,22].

HPFH is a heterogeneous condition that has high expression of γ-globin chains caused by a point mutation in the promoter region of the gene or an imbalance of the α/β-globin chain as a result of a deletion in the β-globin gene [23–25]. HPFH patients have around 10% to 40% HbF of their total hemoglobin, but in those with a genetic deletion in other globin genes, the value may reach 100% [25,26]. HbF is also elevated in pregnant women, cancer patients being treated with hydroxyurea, and in patients with aplastic anemia, hepatoma, or myeloid leukemia [25–27].

Both SCD and thalassemia patients who have high HbF levels have therapeutic advantages, including reduced disease severity and better outcomes [7]. Therapeutic agents, such as the inducer drugs hydroxyurea and thalidomide, are widely used in treating SCD, thalassemia, myelodysplastic anemia, sideroblast anemia, and leukemia by increasing patients’ HbF values [26,28–32]. Hydroxyurea is metabolized to produce nitric oxide and activates gene transcription to promote HbF synthesis [26]. Ribonucleotide reductase is inhibited, thus blocking DNA synthesis, leading to cellular cytotoxicity and suppression of erythroid progenitors, which affects the erythropoiesis kinetics and physiology and leads to recruitment of erythroid progenitors with increased HbF levels [26,28,30,32,33]. A once-daily treatment of SCD with hydroxyurea may produce intermittent cytotoxic suppression of erythroid progenitors and reduce cell-stress signaling, thus altering the kinetics of erythropoiesis and elevated HbF values with erythroid progenitor enrollment (33).

Patients who are unresponsive to hydroxyurea treatment can be treated with sodium butyrate containing micro RNAs to induce HbF synthesis [34,35]. Thalidomide is a synthetic glutamic acid derivative used to treat autoimmune diseases, hematologic disorders, and multiple myeloma by increasing HbF levels and thereby alleviating symptoms [36]. Thalidomide also has a benign toxicity profile and remarkable efficacy in reducing the severity of anemia [37]. The increase in HbF synthesis in patients with blood disorders refines tissue oxygenation and reduces inflammation besides reducing red blood cell membrane damage, diminishing HbS polymerization, and decreasing vasoconstriction and thrombosis [29]. The use of thalidomide may also reduce the incidence of hospitalization and blood transfusion [30].

3. Polymorphisms Regulate the Expression of Fetal Hemoglobin

The expression of HbF is facilitated by the presence of SNPs at three loci: XMN1-HBG2 at 11p15.4, BCL11A at 2p16.1, and the HBS1L-MYB intergenic region at 6q23.3, as shown in Figure 2. These three loci are aligned to increase HbF, accounting for 20–50% of interindividual variation in HbF values [7]. The increase in HbF ameliorates the severity of anemia, which can decrease the need for transfusion and the severity of renal impairment. Regulation of the HbF value requires precise communication among transcription factors to achieve downregulation or activation of genes in these loci (Figure 2).

The presence of SNPs may have implications in a disease, such as increased HbF levels in common and complex diseases or conditions, e.g., drug-induced conditions, SCD, β-thalassemia, anemia, diabetes, chronic kidney failure, malignancies, or obesity in many regions of the world, such as Europe, the Middle East, and Southeast Asia, including Malaysia [20,38–44]. Several SNPs, such as rs11886868, rs766432, rs9399137, rs742144, rs9399137, rs28384513, and rs4671393, are associated with erythropoiesis and HbF augmentation (Table 1 and Figure 2) [45–47]. SNPs are one of genetic variations that may alter the outcome of downstream processes by influencing the promoter activity in gene
expression and stabilizing mRNA, thus allowing expression of a disease or phenotype and traits [12].

Figure 2. Pathway for regulation of γ-globin, possibly an increasing HbF level, and amelioration of anemia in XMN1-HBG2, BCL11A, and HBS1L-MYB by the presence of SNPs, transcription factor, and a therapeutic agent.

Table 1. SNPs found in XMN1-HBG2, BCL11A, and HBS1L-MYB genes.

| Locus          | SNPs                  | Effects of SNPs                                                                 | References |
|----------------|-----------------------|---------------------------------------------------------------------------------|------------|
| XMN1-HBG2      | Rs782144              | HbF level highly expressed, with T allele resulting in mild anemia and asymptomatic state in lenient disease. | [40,41,48] |
|                |                       | The high level of HbF may reduce pain crises, reduce risk of feto-maternal bleeding, reduce blood transfusion requirement, and unusual thalassemia. | [49,50]    |
| BCL11A         | Rs1018987 Rs4127407   | Rs1427407, rs10189857, and rs11886868 had no significant difference in <5% and >5% of HbF level. | [51]       |
|                | Rs766432 Rs11886868 Rs4671393 | The presence of T and G alleles in rs11886868 and rs4671393 is associated with amelioration of SCD phenotype through an increase in HbF level. | [52]       |
|                | Rs6729815 Rs1426407 Rs6545816 | The allele C in rs11886868 and allele A in rs4671393 are linked to increased HbF levels (p = 0.026 and 0.028) but have no correlation with stroke. | [53]       |
|                | Rs7606173 Rs6545817   | The downregulation of BCL11A caused by rs11886868 results in high HbF production (11.36–49.40%) in the CC genotype, followed by CT and TT. | [54]       |
|                |                       | The presence of knockdown of SOX6 and KLF1 may reduce the silencing of the γ-globin gene and enhance HbF levels to more than 28.9%. | [55,56]    |
|                |                       | Hydroxyurea treatment is associated with rs11886868, rs4671393, and rs1427407, which may ameliorate anemia. | [57,58]    |
|                |                       | The HbF levels may be increased due to Rs11886868, which consists of the C allele; this also ameliorates the clinical phenotype. | [59]       |
Table 1. Cont.

| Locus       | SNPs                                      | Effects of SNPs                                                                 | References |
|-------------|-------------------------------------------|---------------------------------------------------------------------------------|------------|
| HBS1L-myb   | Rs4895441, Rs66650371, Rs9399137          | Rs9399137 with C allele associated with increased HbF production and hematologic parameters. | [51]       |
|             | Rs9399137, Rs11759553, Rs28384513         | The decrease in MYB expression in rs66650371 is associated with high HbF synthesis to produce proper RBC and Hb levels. | [60,61]   |
|             | Rs9402686                                 | The rs9402686 at sub-locus is associated with high HbF in the A allele.         | [61]       |

3.1. Epidemiology and Molecular Aspects of XMN1-HBG2

XMN1-HBG2 is a genetic modifier in β-thalassemia, located at −158 upstream of the γ-globin gene on chromosome 11. The polymorphism of XMN1 is expressed in the γ-globin gene in the promoter region by nucleotide substitution of C→T (rs7482144), thus increasing HbF levels and ameliorating the phenotype of β-thalassemia and anemia (Figure 2 [25,42]. Because of increased HbF levels, patients with heterozygous XMN1-HBG2 have only modest clinical manifestations [41].

According to studies on human erythroid progenitor cells, hydroxyurea treatment may increase erythroid differentiation and HbF levels by inducing the expression of the γ-globin gene [64]. While most SNPs in XMN1-HBG2 polymorphism are associated with high HbF values, HbF susceptibility to hydroxyurea treatment is regulated by alternative pathways that protect hematopoietic cells from stress-induced death and push them to endpoint erythroid differentiation [64]. The presence of XMN1-HBG2 polymorphism and treatment interventions, such as with azacytidine and hydroxyurea agents, are associated with minimal need for blood transfusion among blood disorder patients by increasing their HbF levels, resulting in less severe disease.

In Malaysia, both genotypes (CT and TT) of XMN1-HBG2 polymorphism are highly present in Malay β-thalassemia major individuals compared with that in Chinese patients, resulting in high HbF production in the latter [65]. Based on a study in Pakistan [66], the level of HbF is significantly increased in patients with intermediate thalassemia (around 8%) compared with that in thalassemia major patients, with the T allele in XMN1-HBG2 frequently present in the intermediate group. The association of homozygous and heterozygous T alleles in XMN1-HBG2 is also present in milder forms of SCD, where the HbF level is higher in TT allele carriers, followed by CT and CC genotypes (p < 0.01) [20]. The SNP rs7482144 in XMN1-HBG2 has caused a 2.2% variation in HbF expression in African American SCD patients in the United States [47]. In Indonesia, the HbF expression is slightly higher, at 3.2%, and it is even higher in Syria, at 16.3% [39,42,59].

3.2. Epidemiology and Molecular Aspects of HBS1L-MYB

SNPs linked to hematopoietic traits may be identified in a 126-kb intergenic region between HBS1L (Hsp70 subfamily B suppressor 1-like gene) and the MYB (MYB proto-oncogene) at chromosome 6q23 [67,68]. HBS1L-MYB is an intergenic region that increases HbF values in thalassemia and sickle cell anemia and thus ameliorates anemia [67,69].

The c-MYB protein encoded by MYB has cis-regulatory and trans-acting functions in regulating hematopoiesis and erythropoiesis, thus influencing HbF values through an unidentified mechanism. The c-MYB protein is necessary for maintaining erythroid cellular proliferation and equivalence of differentiation. In vitro study of CD34 cells cultured in the presence of erythropoietin, stem cell factor, and transforming growth factor resulted in a decline in cMYB levels in treated cells, which contributed to an increase in γ-globin expression that ultimately increased HbF values [70]. Moreover, the protein produced by HBS1L is a GTPase family for elongation and may have a role in the control of cellular
processes, such as protein synthesis, cytoskeleton assembly, protein trafficking, and signal transduction. Increased γ-globin expression has been induced by secretion-associated and RAS-related proteins and hydroxyurea treatment [71]. HBS1L and MYB transcription is necessary for the enhancement of Hbf levels.

The HBS1L-MYB intergenic region consists of HMIP-1 and HMIP-2 genes, which are HMIP-2A at −84 of the MYB core enhancer, while HMIP-2B is between −71 and −63 of the MYB enhancer element. SNPs correlate with unusually high Hbf levels based on genetic variation. The HBS1L-MYB intergenic polymorphism block 2 (HMIP-2) reveals SNPs that are strongly associated with each other, with a length of around 24 kb, such as rs28385413, rs66650371, rs9399137, rs9389269, rs9402686, rs9494145, and rs9483788 [72].

HBS1L-MYB is also a main regulator of erythropoiesis, and its expression may improve anemia in patients who have renal failure with the presence of rs7776054 and rs6650371 SNPs [73]. Both SNPs are significantly associated with high Hbf levels that may ameliorate SCD and anemia in pregnant women [50,74].

SNPs rs4895441 (A-G), rs9399137 (T-C), and rs28384513 (A-C) are related, with 3.8% to 32% of Hbf level variation in HBS1L-MYB among β-thalassemia/Hbf and homozygous Hbf in the Thai population [51]. The Hbf level among SCD in patients of European descent is similar to the range in Thai patients [51,59]. The SNPs of rs48954419 (A-G), rs9399137 (T-C), and rs28384513 (A-C) have a high possibility of ameliorating severe anemia and hemoglobinopathies, especially with SNP rs9399137, due to significantly different MCV (p < 0.05), MCH (p < 0.05), and Hbf levels (p < 0.05) [51]. Another study in a cohort from Sabah showed that rs9399137 (T-C) and rs11759553 (A-T) SNPs were frequently present in β0-thalassemia patients of Filipino descent (n = 34, MAF = 0.15 and 0.18); these patients have mean Hbf values between 1.7% and 3.4% [63]. Downregulation of MYB expression and activation of HBG expression by termination of the orphan nuclear receptor TR2/TR4 may contribute to the regulation of Hbf gene expression in SNPs of HBS1L-MYB [68].

3.3. Epidemiology and Molecular Aspect of BCL11A

The B-cell lymphoma/leukemia 11A gene (BCL11A), located at chromosome 2, is a transcriptional repressor of the hematopoietic system, especially in Hbf silencing and switching [60]. Increased Hbf levels may be present with the downregulation of BCL11A, which then allows the expression of γ-globin [75,76].

The remarkable hemoglobin shifting is influenced by the expression of the KLF1 (erythroid Kruppel-like factor) gene, which stimulates β-globin production and indirectly represses γ-globin expression [77]. However, downregulation of KLF1 in vivo has revealed a decrease in BCL11A expression in adult erythroid progenitors, which leads to activation of Hbf production in anemic β-thalassemia, SCD, and HPFH patients [78,79]. Furthermore, BCL11A is expressed only when the expression of γ-globin is silenced. SOX6 (Sry-related high-mobility group HMG-box transcription) is a transcription factor that is required for the suppression of γ-globin in humans. SOX6 coexists with the BCL11A gene to produce high levels of Hbf (up to 45% of the red blood cells), while an inconsistent knockdown of BCL11A or SOX6 caused slightly lower induction of Hbf production [55].

Many SNPs may be present in BCL11A. A few of them are associated with lower Hbf levels, such as rs4671393, rs4127407, and rs7606173. However, the same SNPs have also caused high Hbf values by microdeletion [80]. The role of BCL11A should be scrutinized further since, according to a prior study [51], the SNPs rs1426407, rs1018987, and rs11886868 did not have significant differences in hematological parameters. However, attributed to the formation of BCL11A, Hbf levels remained greater (3.9% to 34.2%) than normal (1%) with mild or moderate anemia in homozygous Hbf and β-thalassemia/Hbf individuals [51].

In SCD patients, the rs11886868 (C-T) and rs4671393 (A-G) SNPs are significantly associated with high Hbf levels. The switch to T and G base pairs is high in those with <15% Hbf, while C and A are present in those with Hbf levels >15% [52]. A previous study revealed that the abolishment of the BCL11A binding domain within the silencing mode at the 5′ δ-globin gene will enhance the Hbf level, and this could minimize the complications
of SCD [81]. Another study discovered that the rs4671393 has potential to ameliorate the anemia due to the presence of a G allele in the genotypes that can increase the HbF levels in SCD patients [82]. A study in the Sub-Saharan region found that the BCL11A loci is crucial in HbF regulation and also showed a negative association between the incidence of ischemic stroke and the level of HbF, where SCD patients with stroke had significantly low mean HbF compared to the group that did not have stroke ($p = 0.024$) [53].

The SNPs rs6545816 (A/C), rs6545817 (A/G), rs766432 (A/C), and rs6729815 (A/G) are associated with high HbF levels ($p < 0.001$), whereas 3.3% of HbF level variation has the highest association with rs6729815 in β-thalassemia/HbE among Thai patients [83]. Due to the stress of erythropoiesis, rs118868686 with C alleles is more strongly associated with β-thalassemia, HPFH, and SCD than in non-anemic populations in progressing to a milder phenotype [58]. A similar study of Indonesian individuals with HbE/β-thalassemia and moderate anemia found a significant association between HbF levels and SNPs rs766432 ($n = 117$) and rs11886868 ($n = 117$) through the presence of C alleles in ameliorating clinical severity [41,83]. A few SNPs, such as rs1886868, rs4671393, and rs1427407, are involved in the downregulation of BCL11A with elevated HbF levels in hydroxyurea treatment [57,58]; this finding indicates that the downregulation of BCL11A expression may be beneficial by ameliorating symptoms of anemia through increased HbF levels. Therefore, BCL11A down-regulation or domain blockage can be a guide for new targeted therapies in SCD and β-thalassemia major patients [57,58,83].

4. Genotyping Technologies in Single Nucleotide Polymorphism Recognition

Alteration of a single base, resulting in SNPs, may involve the insertion, substitution, fusion, or duplication of a nucleotide. These SNPs may serve as genetic markers in clinical practice, and the SNPs or mutations may be linked to disease susceptibility, etiology, and pharmacogenomics. Such genotyping has been widely accepted, especially in pharmacogenomic studies, to avoid clinical problems such as adverse drug reactions in chronic and inherited diseases [84]. The detection of SNPs also is used to identify specific sites in genes associated with high HbF levels, which may confer therapeutic benefits on patients with blood disorders [85]. Several methods use allele discrimination procedures, as shown in Figure 3 [86].

![Figure 3. SNP genotyping in allele discrimination to increase the number of molecules for the detection of SNPs of interest in disease states.](image-url)

The allelic discrimination assay is a high throughput final assay for pinpointing polymorphisms in a single nucleic acid sequence. Even though each reaction involves two primer/probe pairs, genotyping the two potential polymorphisms at the SNP location in the target template sequence is necessary [86]. The primer extension consists of three types—common primer extension, specific primer extension, and allele-specific primer extension—that may straightforwardly accomplish allelic discrimination in a DNA template and are
acceptable for the detection of multiple SNPs [84]. The primer extension reaction products can be detected by electrophoresis, fluorescence, pyrosequencing, mass spectrometry, or microarray [84,87].

Allele-specific probes comprising fluorescein-labeled complementary DNA or RNA can be used to differentiate SNPs through their binding stability on target sequences. Unmatched strands of the probes will be washed away, while matched pairs will bind to the SNP targets [84,87]. Hybridization-based SNP genotyping can be carried out using microarray or chip-based technologies, TaqMan assay, a combination of matrix-assisted laser desorption ionization, time-of-flight mass spectrometry quantum beads, and dynamic allele-specific hybridization [84,87–89]. The hybridization of two oligonucleotides occurs through ligation catalyzed by DNA ligase to form single oligonucleotides between the allele-specific probe and common oligonucleotides [90].

The ligation required to form single oligonucleotides from hybridization of two oligonucleotides requires three types of probes (two allele-specific and one common probe) for attachment of template adjacent to the SNP, which reveals a specific SNP position [87]. The ligation also uses combinatorial fluorescence energy transfer (CFET) or padlock as a specific probe. CFET consists of fluorescence that can be used with biotinylated (common probes) to detect SNP by capillary array electrophoresis [84]. In the Padlock technique, a linear oligonucleotide probe with the imitations of allele-specific and common probes is prepared for ligation at the SNP site [84,91]. The complete match forms the circular strand product by using rolling circle amplification, conventional PCR, or microarray [91].

For an enzymatic cleavage, such as flap endonuclease, a restriction enzyme is needed for discrimination of alleles in SNP genotyping [84]. The enzymatic cleavage technique consists of two molecular assays for genetic variation: restriction fragment length polymorphism (RFLP) and an Invader® assay. Due to its relatively low cost and small amount of probe needed, RFLP is widely used to identify the cleavage site in double-stranded DNA for synthesizing short DNA fragments in SNP genotyping; straightforward techniques and fewer probes are needed, but the number of SNP that can be detected is limited [14,92]. The Invader® assay consists of a structure-specific cleavage by flap endonuclease enzyme and probes to hybridize with the DNA target [93]. Three probes bind to the compatible 5’-site of the SNP sites, using allele-specific probes, whereas the probes are complementary to the 3’-site [14,84,94]. Thus, the three-dimensional structure is formed, and the SNP site can be directly observed by fluorescence analysis [93].

Genotyping techniques are important in biomedical applications, where they can discriminate more than one allele of SNPs. Allele discrimination methods are used in numerous well-established SNPs genotyping technologies: Beadchip, Genechip, pyrosequencing, RFLP, MassEXTEND, Taqman, ARMS-PCR, and Invader®. Genotyping is useful also in the detection of genetic diseases; chronic disease such as anemia, cancer, Alzheimer’s disease, arthritis, diabetes, and blood disease; and in pharmacogenomic studies. The polymorphism advanced assay methods are accurate, sensitive, error-free, and cost-effective. They are beneficial in molecular studies, especially in the healthcare industry and advanced biology [84].

5. Conclusions
Anemia can be a manifestation of hemoglobinopathies, such as thalassemia and SCD, that disrupt the function of red blood cells, resulting in a lack of oxygen transported to tissues and organs. The severity of anemia can be ameliorated by the production of HbF. A high HbF level may play an important role in regulating erythropoiesis in acquired or inherited conditions of anemia. The potential to increase HbF levels is also associated with the presence of SNPs within three QTLs, XMN1-HBG2, HBS1L-MYB, and BCL11A, which can increase the production of HbF as a compensatory mechanism in blood diseases. Many SNP genotyping technologies with allele discrimination may be used to conduct genome-wide association studies, which can provide useful information on healthcare and complications of care. Furthermore, these genetic modifiers are also associated with disease
prognosis. The use of QTL in patients with high HbF values can aid in genetic counseling for inherited anemia diseases and in the prescribing of medications.

**Author Contributions:** Conceptualization, S.N.N.A.M.; software, M.N.H.; writing—original draft preparation, S.N.N.A.M.; writing—review and editing, Z.Z., M.A., W.S.W.A.R., H.A.E. and S.I. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research was funded by the Ministry of Higher Education Malaysia for Fundamental Research Grant Scheme. Project Code: [FRGS/1/2019/SKK06/USM/02/8].

**Institutional Review Board Statement:** Not applicable.

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** The data presented in this study are available on request from the corresponding author.

**Acknowledgments:** The authors thank Universiti Sains Malaysia for the administrative support.

**Conflicts of Interest:** The authors declare no conflict of interest.

**References**

1. Weiss, G.; Goodnough, L.T. Anemia of Chronic Disease. *N. Engl. J. Med.* **2005**, *352*, 1011–1023. [CrossRef] [PubMed]
2. Madu, A.J.; Ughasoro, M.D. Anaemia of Chronic Disease: An In-Depth Review. *Med Princ. Pract.* **2017**, *26*, 1–9. [CrossRef] [PubMed]
3. Chaparro, C.M.; Suchdev, P.S. Anemia epidemiology, pathophysiology, and etiology in low- and middle-income countries. *Ann. N. Y. Acad. Sci.* **2019**, *1450*, 15–31. [CrossRef] [PubMed]
4. Domenica Cappellini, M.; Motta, I. Anemia in Clinical Practice: Definition and Classification: Does Hemoglobin Change with Aging? *Semin. Hematol.* **2015**, *52*, 261–269. [CrossRef] [PubMed]
5. Chulilla, J.A.M.; Colás, M.S.R.; Martin, M.G. Classification of anemia for gastroenterologists. *World J. Gastroenterol.* **2009**, *15*, 4627–4637. [CrossRef]
6. Akinsheye, I.; Alsultan, A.; Solovieff, N.; Ngo, D.; Baldwin, C.T.; Sebastiani, P.; Chui, D.H.K.; Steinberg, M.H. Fetal hemoglobin in pathology and health at the basic laboratory level: New and known γ -gene mutations associated with hereditary persistence of fetal hemoglobin. *Int. J. Lab. Hematol.* **2014**, *36*, 13–19. [CrossRef]
7. Thein, S.L.; Menzel, S. Discovering the genetics underlying foetal haemoglobin production in adults. *Br. J. Haematol.* **2009**, *145*, 455–467. [CrossRef]
8. Akinsehẹ, I.; Alsultan, A.; Solovieff, N.; Ngo, D.; Baldwin, C.T.; Sebastiani, P.; Chui, D.H.K.; Steinberg, M.H. Fetal hemoglobin in sickle cell anemia. *Blood* **2011**, *118*, 19–27. [CrossRef]
9. Thein, S.L.; Menzel, S. Discovering the genetics underlying foetal haemoglobin production in adults. *Br. J. Haematol.* **2009**, *145*, 455–467. [CrossRef]
10. Fanis, P.; Kousiappa, I.; Phylactides, M.; Kleanthous, M. Genotyping of BCL11A and HBS1L-MYB SNPs associated with fetal haemoglobin levels: A SNaPshot minisequencing approach. *BMC Genom.* **2014**, *15*, 108. [CrossRef]
11. Zakaria, N.; Islam, A.; Abdullah, W.; Bahar, R.; Yusoff, A.M.; Wahab, R.A.; Shamsuddin, S.; Johan, M. Epigenetic Insights and Potential Modifiers as Therapeutic Targets in β-Thalassemia. *Biomolecules* **2021**, *11*, 755. [CrossRef] [PubMed]
12. Shastris, B.S. SNPs: Impact on gene function and phenotype. *Methods Mol. Biol.* **2009**, *578*, 3–22. [CrossRef] [PubMed]
13. Ismail, S.; Essawi, M. Genetic polymorphism studies in humans. *Middle East J. Med. Genet.* **2012**, *1*, 57–63. [CrossRef]
14. Sukhumristchait, W. Polymorphisms. In *Genetic Diversity and Disease Susceptibility*; BoD: Norderstedt, Germany, 2018; Available online: http://www.intechopen.com/books/genetic-diversity-and-disease-susceptibility/polymorphisms (accessed on 7 February 2022).
15. Lambert, G.; Tsinajinnie, D.; Duggan, D. Single Nucleotide Polymorphism Genotyping Using BeadChip Microarrays. *Curr. Protoc. Hum. Genet.* **2013**, *78*, 2–9. [CrossRef]
16. Butler, J.M.; Coble, M.; Vallone, P. STRs vs. SNPs: Thoughts on the future of forensic DNA testing. *Forensic Sci. Med. Pathol.* **2007**, *3*, 200–205. [CrossRef]
17. Teama, S. DNA Polymorphisms: DNA-Based Molecular Markers and Their Application in Medicine. In *Genetic Diversity and Disease Susceptibility*; BoD: Norderstedt, Germany, 2018; Available online: https://www.intechopen.com/chapters/62578 (accessed on 9 May 2022).
18. Vallejos-Vidal, E.; Reyes-Cerpa, S.; Rivas-Pardo, J.A.; Maíseych, K.; Yáñez, J.M.; Valenzuela, H.; Cea, P.A.; Castro-Fernandez, V.; Tort, L.; Sandino, A.M.; et al. Single-Nucleotide Polymorphisms (SNP) Mining and Their Effect on the Tridimensional Protein Structure Prediction in a Set of Immunity-Related Expressed Sequence Tags (EST) in Atlantic Salmon (*Salmo salar*). *Front. Genet.* **2020**, *10*, 1406. [CrossRef]
19. Edoh, D.; Antwi-Boasiako, C.; Amuzu, D. Fetal hemoglobin during infancy and in sickle cell adults. Afr. Health Sci. 2006, 6, 51–54. [CrossRef]

20. Dadheech, S.; Jain, S.; Madhulatha, D.; Sharma, V.; Joseph, J.; Jothy, A.; Munshi, A. Association of Xmn1 −158 γG variant with severity and HbF levels in β-thalassemia major and sickle cell anaemia. Mol. Biol. Rep. 2014, 41, 3331–3337. [CrossRef]

21. Thein, S.L. Molecular basis of β-thalassemia and potential therapeutic targets. Blood Cells Mol. Dis. 2018, 70, 54–65. [CrossRef]

22. Gardner, K.; Fulford, T.; Silver, N.; Rooks, H.; Angelis, N.; Allman, M.; Nkya, S.; Makani, J.; Howard, J.; Kesse-Adu, R.; et al. G(HbF): A genetic model of fetal hemoglobin in sickle cell disease. Blood Adv. 2018, 2, 235–239. [CrossRef]

23. Lim, W.F.; Munandi, L.; George, E.; Sathar, J.; Teh, L.; Lai, M.I. HbF in HbE/β-thalassemia: A clinical and laboratory correlation. Hematology 2014, 20, 349–353. [CrossRef] [PubMed]

24. Farrell, J.J.; Sherva, R.; Chen, Z.-Y.; Luo, H.; Chu, B.F.; Ha, S.Y.; Li, C.K.; Lee, A.; Li, R.C.H.; Yuen, H.L.; et al. A 3-bp deletion in the intron 1 promoter region of the G6PD gene and the G(HbF) model in South East Asian subjects. Acta Haematol. 2006, 115, 33–39. [CrossRef] [PubMed]

25. Hossain, M.; Noor, F.; Bhuyan, G.S.; Qadri, S.S.; Mannoor, K. Role of Xmn1 polymorphism in HbF induction in HbE/β-thalassemia patients. Bangladesh Med. Res. Counc. Bull. 2019, 45, 133–142. [CrossRef]

26. Sokolova, A.; Mararenko, A.; Rozin, A.; Podrumar, A.; Gottlieb, V. Hereditary persistence of hemoglobin F is protective against red cell sickling. A case report and brief review. Hematol. Oncol. Stem Cell Ther. 2019, 12, 215–219. [CrossRef] [PubMed]

27. Wood, W.G. Increased HbF in adult life. Bailliere’s Clin. Haematol. 1993, 6, 177–213. [CrossRef]

28. Fitzhugh, C.D.; Hsieh, M.M.; Allen, D.; Coles, W.A.; Seamon, C.; Ring, M.; Zhao, X.; Minniti, C.P.; Rodgers, G.P.; Schechter, A.N.; et al. Hydroxyurea-Increased Fetal Hemoglobin Is Associated with Less Organ Damage and Longer Survival in Adults with Sickle Cell Anemia. PLoS ONE 2015, 10, e0141706. [CrossRef] [PubMed]

29. Lübbert, M.; Iborst, G.; Sander, P.; Bogatyreva; L.; Becker, H.; Wijermans, P.W.; Suciu, I.; Bissé, E.; Claus, R. Elevated fetal haemoglobin is a predictor of better outcome in MDS/AML patients receiving 5-aza-2’-deoxycytidine (Decitabine). Br. J. Haematol. 2017, 176, 609–617. [CrossRef]

30. Pule, G.D.; Mowla, S.; Novitzky, N.; Wiysonge, C.S.; Wonkam, A. A Systematic Review of Known Mechanisms of Hydroxyurea-induced Foetal Haemoglobin for Treatment of Sickle Cell Disease. Expert Rev. Hematol. 2015, 8, 669–679. [CrossRef]

31. Mosca, A.; Paleari, R.; Leone, D.; Ivaldi, G. The relevance of hemoglobin F measurement in the diagnosis of thalassemias and related hemoglobinopathies. Clin. Biochem. 2009, 42, 1797–1801. [CrossRef]

32. Karimi, M.; Zarei, T.; Haghpanah, S.; Moghadam, M.; Ebrahimi, A.; Rezaei, N.; Heidari, G.; Vazin, A.; Khavari, M.; Miri, H. Relationship between Single-nucleotide Polymorphism and Response to Hydroxyurea Therapy in Iranian Patients with β-Thalassemia Intermedia. J. Pediatr. Hematol. 2017, 39, e171–e176. [CrossRef]

33. Ware, R.E. How I use hydroxyurea to treat patients with sickle cell anemia. Blood 2010, 115, 5300–5311. [CrossRef]

34. Panja, A.; Basu, A. Pharmacogenomics of the Drugs used for the Treatment of Thalassemia. J. Cytol. Histol. 2015, 6, 5. Available online: https://www.readcube.com/articles/10.4172%2F2157-7099.1000360 (accessed on 25 January 2022).

35. Tayebi, B.; Abrishami, F.; Alizadeh, S.; Minayi, N.; Mohammadian, M.; Soleimani, M.; Dehghanifarad; A.; Atwan, H.; Ajami, M.; Ajami, M. Modulation of microRNAs expression in hematopoietic stem cells treated with sodium butyrate in inducing fetal hemoglobin expression. Artif. Cells Nanomed. Biotechnol. 2016, 44, 146–156. [CrossRef] [PubMed]

36. Aerbajinai, W.; Zhu, J.; Gao, Z.; Chin, K.; Rodgers, G.P.; Thalidomide induces γ-globin gene expression through increased reactive oxygen species–mediated p38 MAPK signaling and histone H4 acetylation in adult erythropoiesis. Blood 2007, 110, 2864–2871. [CrossRef] [PubMed]

37. Lu, Y.; Wei, Z.; Yang, G.; Lai, Y.; Liu, R. Investigating the Efficacy and Safety of Thalidomide for Treating Patients With β-Thanasemia: A Meta-Analysis. Front. Pharmacol. 2022, 12, 3959. [CrossRef] [PubMed]

38. Yamada, T.; Morikawa, M.; Yamada, T.; Nishida, R.; Takeda, M.; Kawaguchi, S.; Minakami, H. Changes in hemoglobin F levels in pregnant women unaffected by clinical fetomaternal hemorrhage. Clin. Chim. Acta 2013, 415, 124–127. [CrossRef] [PubMed]

39. Kahhaleh, F.; Sulaiman, M.A.; Alquobayil, F. Association of Xmn1 polymorphism with consanguineous marriage with fetal hemoglobin in Syrian patients with sickle cell disease. Cogent Med. 2019, 6, 1639243. Available online: https://www.tandfonline.com/action/journalInformation?journalCode=oam20 (accessed on 6 January 2021).

40. Prasing, W.; Odawara, T.; Traisathit, P.; Yamashiro, Y.; Hattori, Y.; Pornprasert, S. Analysis of theXmn1-G variant with G6PD deficiency and its association with hemoglobin F levels. Int. J. Lab. Hematol. 2015, 37, e25–e28. [CrossRef]

41. Ruitto, L.; Basalamah, M.; Siswandari, W.; Setyono, J.; Wulandari, G.; Mulatsih, S.; Sofro, A.S.M.; Sadewa, A.H.; Sutaryo, S. Modifying effect of XmnI, BCL11A, and HBS1L-MYB on clinical appearances: A study on β-thalassemia and hemoglobin E/β-thalassemia patients in Indonesia. Hematol. Oncol. Stem Cell Ther. 2016, 9, 55–63. [CrossRef]

42. Yusof, W.; Zulkifli, M.M.; Azman, N.F.; Ab Hamid, S.A.; Othman, A.; Draman, N.; Zilfalil, B.A.; Hassan, R.; Abdullah, W.Z. Factors affecting health-related quality of life and its association with the Xmn1-G polymorphism among adolescents with transfusion-dependent beta thalassemia and HbE/β-thalassemia in East Coast Malaysia. Pediatr. Hematol. Oncol. J. 2020, 5, 30–36. [CrossRef]

43. Sivalingam, M.; Looi, M.L.; Zakaria, S.Z.S.; Hamidah, N.H.; Alias, H.; Latiff, Z.A.; Ibrahim, H.; Jamal, R. Molecular study and genotype/phenotype correlation of β-thalassemia in Malaysia. Int. J. Lab. Hematol. 2012, 34, 377–382. [CrossRef]
Diagnostics 2022, 12, 1374

44. Green, N.S.; Barral, S. Genetic modifiers of HbF and response to hydroxyurea in sickle cell disease. Pediatr. Blood Cancer 2011, 56, 177–181. [CrossRef] [PubMed]

45. Lettre, G.; Sankaran, V.G.; Andrade Bezerra, M.C.; Araújo, J.A.; Uda, M.; Sanna, S. DNA polymorphisms at the BCL11A, HBS1L-MYB, and -globin loci associate with fetal hemoglobin levels and pain crises in sickle cell disease. Proc. Natl. Acad. Sci. USA 2008, 105, 11869–11874. [CrossRef] [PubMed]

46. Nuinoon, M.; Kruachan, K.; Sengking, W.; Horpet, D.; Sungyuan, U. Thalassemia and Hemoglobin E in Southern Thai Blood Donors. Adv. Hematol. 2014, 2014, 92306. [CrossRef] [PubMed]

47. Badens, C.; Joly, P.; Agouti, I.; Thuret, I.; Gommet, K.; Fontambrina, S.; Simeoni, M.C.; Loundou, A.; Pissard, S. Variants in genetic modifiers of β-Thalassemia can help to predict the major or intermediate type of the disease. Haematologia 2011, 96, 1712–1714. [CrossRef]

48. Nuntakarn, L.; Fucharoen, S.; Fucharoen, G.; Sanchaisuriya, K.; Jetsrisuparb, A.; Wangnnon, S. Molecular, hematological and clinical aspects of thalassemia major and thalassemia intermedia associated with Hb E-β-thalassemia in Northeast Thailand. Blood Cells Mol. Dis. 2009, 42, 32–35. [CrossRef]

49. Allard, P.; Alhaj, N.; Lobitz, S.; Cario, H.; Jarisch, A.; Grosse, R.; Oevermann, L.; Hakimeh, D.; Tagliaferri, L.; Kohne, E.; et al. Genetic modifiers of fetal hemoglobin affect the course of sickle cell disease in patients treated with hydroxyurea. Haematologica 2021. Available online: https://pubmed.ncbi.nlm.nih.gov/34706496/ (accessed on 26 January 2022).

50. Lolis, D.; Georgiou, I.; Loizou, P.; Makrydimas, G. High HbF in pregnancy is associated with the Xmn I polymorphism at the -158bp of the Gq-globin gene. Eur. J. Obstet. Gynaecol. Reprod. Biol. 1995, 60, 153–156. [CrossRef]

51. Prasing, W.; Mekki, C.; Traisathit, P.; Pissard, S.; Pornprasert, S. Genotyping of BCL11A and HBS1L-MYB Single Nucleotide Polymorphisms in β-thalassemia/HbE and Homozygous HbE Subjects with Low and High Levels of HbF. Walidatk J. Sci. Technol. 2018, 15, 627–636. [CrossRef]

52. Chaouch, L.; Moumni, I.; Ouragini, H.; Darragi, I.; Kalai, M.; Chaouachi, D.; Boudrigua, I.; Hafsia, R.; Abbes, S. rs11886868 and rs4671393 of BCL11A associated with fetal level variation and modulate clinical complications among Filipino sickle cell anemia patients. Hematology 2016, 21, 425–429. [CrossRef]

53. Nicolau, M.; Vargas, S.; Silva, M.; Coelho, A.; Ferreira, E.; Mendonça, J.; Vieira, L.; Kjöllerström, P.; Maia, R.; Silva, R.; et al. Genetic modulators of fetal hemoglobin expression and ischemic stroke occurrence in African children with sickle cell anemia. Ann. Hematol. 2019, 98, 2673–2681. [CrossRef]

54. Dadheech, S.; Madhulatha, D.; Jain, S.; Joseph, J.; Jothy, A.; Munshi, A. Association of BCL11A genetic variant (Rs11886868) with severity β-thalassemia major & sickle cell anemia. Indian J. Med. Res. 2016, 143, 449–454.

55. Xu, J.; Sankaran, V.G.; Ni, M.; Menne, T.F.; Pissard, S.; Pommprasert, S. Transcriptional silencing of γ-globin by BCL11A involves long-range interactions and cooperation with SOX6. Genes Dev. 2010, 24, 783–789. [CrossRef]

56. Wilber, A.; Nienhaus, A.W.; Persons, D.A. Transcriptional regulation of fetal to adult hemoglobin switching: New therapeutic opportunities. Blood 2011, 117, 3945–3953. [CrossRef] [PubMed]

57. El-Ghamrawy, M.; Yassa, M.E.; Tousson, A.M.S.; El-Hady, M.A.; Mikhail, E.; Mohamed, N.B.; Khorsheid, M.M. Association between BCL11A, HBS1L-MYB, and Xmn1 γG-158 (C/T) gene polymorphism and hemoglobin F level in Egyptian sickle cell disease patients. Ann. Hematol. 2020, 99, 2279–2288. [CrossRef] [PubMed]

58. Friedrisch, J.R.; Sheehan, V.; Flanagan, J.M.; Bittar, C.M.; Wilke, I.I.; Ribeiro, C.B.; Fridrich, B.K.; Hoffmann, A.; Busonero, F.; Maschio, A.; et al. Genome-wide association study shows BCL11A associated with persistent fetal hemoglobin and amelioration of the phenotype of thalassemia. Proc. Natl. Acad. Sci. USA 2008, 105, 1620–1625. [CrossRef] [PubMed]

59. Menzel, S.; Jiang, J.; Silver, N.; Gallagher, J.; Cunningham, J.; Durudescu, G.; Lathrop, M.; Farrall, M.; Spector, T.D.; Thein, S.L. The HBS1L-MYB intergenic region on chromosome 6q23.3 influences erythrocyte, platelet, and monocyte counts in humans. Blood J. Am. Soc. Hematol. 2007, 105, 3624–3626. [CrossRef] [PubMed]

60. Menzel, S.; Jiang, J.; Silver, N.; Gallagher, J.; Cunningham, J.; Durudescu, G.; Lathrop, M.; Farrall, M.; Spector, T.D.; Thein, S.L.; Menzel, S. A survey of genetic fetal-haemoglobin modifiers in Nigerian patients with sickle cell anaemia. PLoS ONE 2018, 13, e0197927. [CrossRef]

61. The, L.K.; Yu, K.S.; Chua, S.M.; George, E.; Lai, M.I.; Wong, L. Genetic Variants in HBS1L-MYB rs9399137 and rs11759553 Associated with Elevated HbF Levels Among Filipino β-°-deletion Carriers. J. Biomed. Clin. Sci. 2017, 2, 28–29.

62. Lim, L.N.; Teh, L.K.; Yu, K.S.; Chua, S.M.; George, E.; Lai, M.I.; Wong, L. Genetic variants of HBS1L-MYB with Hb subtypes level among Filipino β-thalassemia patients is determined by the stress response adaptation of erythroid progenitors and their differentiation propensity. Haematologica 2013, 98, 696–704. [CrossRef]

63. Wong, H.; Mylrea, K.; Feber, J.; Drukker, A.; Filler, G. Prevalence of complications in children with chronic kidney disease according to KDOQI. Kidney Int. 2006, 70, 585–590. [CrossRef] [PubMed]
66. Bashir, S.; Mahmood, S.; Mohsin, S.; Tabassum, I.; Ghafoor, M.; Sajjad, O. Modulatory effect of single nucleotide polymorphism in Xmn1, BCL11A and HBS1L-MYB loci on foetal haemoglobin levels in β-thalassemia major and Intermedia patients. J. Pak. Med. Assoc. 2021, 71, 1394–1398. [CrossRef] [PubMed]

67. Stadtholders, R.; Aktuna, S.; Thongjuea, S.; Aghajanierefa, A.; Pourfarzad, F.; van Iljken, W.; Lenhard, B.; Rooks, H.; Best, S.; Menzel, S.; et al. HBS1L-MYB intergenic variants modulate fetal hemoglobin via long-range MYB enhancers. J. Clin. Investig. 2014, 124, 1699–1710. [CrossRef] [PubMed]

68. Pandit, R.A.; Svasti, S.; Sripricha, O.; Munkongdee, T.; Triwitayakorn, K.; Winichagoon, P.; Fucharoen, S.; Peerapittayamongkol, C. Association of SNP in exon 1 of HBS1L with hemoglobin F level in β0-thalassemia/hemoglobin E. Int. J. Hematol. 2008, 88, 357–361. [CrossRef]

69. So, C.C.; Song, Y.Q.; Tsang, S.T.; Tang, L.F.; Chan, A.Y.; Ma, E.S.; Chan, L.C. The HBS1L-MYB intergenic region on chromosome 6q23 is a quantitative trait locus controlling fetal haemoglobin level in carriers of beta-thalassaemia. J. Med. Genet. 2008, 45, 745–751. [CrossRef]

70. Jiang, J.; Best, S.; Menzel, S.; Silver, N.; Lai, M.I.; Surdulescu, G.L.; Tpector, T.D.; Thein, S.L. cMYB is involved in the regulation of fetal hemoglobin production in adults. Blood 2006, 108, 1077–1083. [CrossRef]

71. Thein, S.L.; Menzel, S.; Peng, X.; Best, S.; Jiang, J.; Close, J.; Silver, N.; Gerovasili, A.; Ping, C.; Yamaguchi, M.; et al. Intergenic variants of HBS1L-MYB are responsible for a major quantitative trait locus on chromosome 6q23 influencing fetal hemoglobin levels in adults. Proc. Natl. Acad. Sci. USA 2007, 104, 11346–11351. [CrossRef]

72. Menzel, S.; Thein, S.L. Genetic Modifiers of Fetal Haemoglobin in Sickle Cell Disease. Mol. Diagnosis Ther. 2018, 23, 235–244. [CrossRef]

73. Beverborg, N.G.; Verweij, N.; Klip, I.T.; van der Wal, H.H.; Voors, A.A.; van Veldhuisen, D.J.; Gansweerto, R.T.; Bakker, S.J.L.; van der Harst, P.; van der Meer, P. Erythropoietin in the General Population: Reference Ranges and Clinical, Biochemical and Genetic Correlates. PloS ONE 2015, 10, e0125215. Available online: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0125215 (accessed on 7 December 2021).

74. Jiwu, L.; Manna, S.; Lai, M.; Ying, Z.; Yanhui, L. Hyperhaemolysis in a pregnant woman with a homozygous β0-thalassemia mutation and two genetic modifiers. Mol. Genet. Genom. Med. 2021, 9, e1696. Available online: https://pubmed.ncbi.nlm.nih.gov/34387288/ (accessed on 17 December 2021).

75. Liu, N.; Hargreaves, V.V.; Zhu, Q.; Kurland, J.V.; Hong, J.; Kim, W.; Sher, F.; Trevino, C.M.; Rogers, J.M.; Kurita, R.; et al. Direct Promoter Repression by BCL11A Controls the Fetal to Adult Hemoglobin Switch. Cell 2018, 173, 430–442.e17. [CrossRef] [PubMed]

76. Sankaran, V.G.; Menne, T.F.; Xu, J.; Akie, T.E.; Lettre, G.; Van Handel, B.; Mikkola, H.K.A.; Hirschhorn, J.N.; Cantor, A.B.; Orkin, S.H. Human Fetal Hemoglobin Expression Is Regulated by the Developmental Stage-Specific Repressor BCL11A. Science 2008, 322, 1839–1842. [CrossRef] [PubMed]

77. Shen, Y.; Li, R.; Teichert, K.; Montbleau, K.E.; Verboon, J.M.; Voit, R.A.; Sankaran, V.G. Pathogenic BCL11A variants provide insights into the mechanisms of human fetal hemoglobin silencing. PLoS Genet. 2021, 17, e1009835. [CrossRef] [PubMed]

78. Zhou, D.; Liu, K.; Sun, C.W.; Pawlik, K.M.; Townes, T.M. KLF1 regulates BCL11A expression and γ- to β-globin gene switching. Nat. Genet. 2010, 42, 742–744. [CrossRef]

79. Bauer, D.E.; Orkin, S.H. Update on fetal hemoglobin gene regulation in hemoglobinopathies. Curr. Opin. Pediatr. 2011, 23, 1–8. [CrossRef]

80. Basak, A.; Hancarova, M.; Ulirsch, J.; Balci, T.; Trkova, M.; Pelisek, M.; Vlckova, M.; Muzikova, K.; Cermak, J.; Trka, J.; et al. BCL11A deletions result in fetal hemoglobin persistence and neurodevelopmental alterations. J. Clin. Investig. 2015, 125, 2363–2368. [CrossRef]

81. Ghedira, E.S.; Lecerf, L.; Faubert, E.; Costes, B.; Moradkhani, K.; Bachir, D.; Galactéros, F.; Pissard, S. Estimation of the difference in HbF expression due to loss of the 5′-δ-globin BCL11A binding region. Haematologica 2013, 98, 305–308. [CrossRef]

82. Qadah, T.; Noorwali, A.; Alzahrani, F.; Banjar, A.; Filimban, N.; Felimban, R. Detection of BCL11A and HBS1L-MYB Genotypes in Foetal Haemoglobin in the Yemeni Population. Qual. Life Res. 2010, 19, 303–314. [CrossRef]

83. Kim, S.; Misra, S. SNP genotyping: Technologies and biomedical applications. Annu. Rev. Biomed. Eng. 2007, 9, 289–320. [CrossRef]

84. Chamounine, A.; Saandi, T.; Mouslak, M.; Larmaraud, J.; Lambrecht, L.; Poisson, J.; Balici, J.; Pissard, S.; Elenga, N. High fetal hemoglobin level is associated with increased risk of cerebral vasculopathy in children with sickle cell disease in Mayotte. BMC Pediatr. 2020, 20, 302. [CrossRef] [PubMed]

85. Fedick, A.; Su, J.; Treff, N.R. Development of TaqMan allelic discrimination based genotyping of large DNA deletions. Genomics 2012, 99, 127–131. [CrossRef] [PubMed]

86. Litos, I.K.; Ioannou, P.C.; Christopoulos, T.K.; Traeger-Synodinos, J.; Kanavakis, E. Genotyping of Single-Nucleotide Polymorphisms by Primer Extension Reaction in a Dry-Reagent Dipstick Format. Anal. Chem. 2006, 79, 395–402. [CrossRef] [PubMed]

87. Walker, J.; Flower, D.; Rigley, K. Microarrays in hematology. Curr. Opin. Hematol. 2002, 9, 23–29. [CrossRef] [PubMed]
89. Prince, J.A.; Feuk, L.; Howell, W.M.; Jobs, M.; Emahazion, T.; Blennow, K.; Brookes, A.J. Robust and Accurate Single Nucleotide Polymorphism Genotyping by Dynamic Allele-Specific Hybridization (DASH): Design Criteria and Assay Validation. *Genome Res.* **2001**, **11**, 152–162. [CrossRef]

90. Bruse, S.E.; Moreau, M.P.; Azaro, M.A.; Zimmerman, R.; Brzustowicz, L.M.; Moreau, M.P.; Hoffman, A. Improvements to bead-based oligonucleotide ligation SNP genotyping assays. *BioTechniques* **2008**, **45**, 559–571. [CrossRef] [PubMed]

91. Szemes, M.; Bonants, P.; De Weerdt, M.; Baner, J.; Landegren, U.; Schoen, C.D. Diagnostic application of padlock probes–multiplex detection of plant pathogens using universal microarrays. *Nucleic Acids Res.* **2005**, **33**, e70. [CrossRef] [PubMed]

92. Dai, S.; Long, Y. Genotyping analysis using an RFLP assay. *Methods Mol. Biol.* **2015**, **1245**, 91–99. [CrossRef] [PubMed]

93. Rao, K.V.N.; Stevens, P.W.; Hall, J.G.; Lyamichev, V.; Neri, B.P.; Kelso, D.M. Genotyping single nucleotide polymorphisms directly from genomic DNA by invasive cleavage reaction on microspheres. *Nucleic Acids Res.* **2003**, **31**, e66. [CrossRef]

94. Olivier, M. The Invader® assay for SNP genotyping. *Mutat. Res.* **2005**, **573**, 103. [CrossRef]